16
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T3189 | B7/CD28 interaction inhibitor 1 | CTLA-4 inhibitor | Others |
B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor. | |||
T78261 | Anti-Mouse CTLA-4 Antibody (9D9) | ||
Anti-Mouse CTLA-4 Antibody is a mouse-derived IgG2b inhibitor targeting CTLA-4 in murine systems. | |||
T9906 | Ipilimumab | Others | |
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. | |||
T77466 | Tremelimumab | Ticilimumab,CP-675206 | Others |
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and l... | |||
T6741 | SPDP | SPDP Crosslinker | Others |
SPDP is a short-chain crosslinker, which is used for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. SPDP could ... | |||
T81329 | Quavonlimab | MK-1308 | |
Quavonlimab (MK-1308) is a novel antibody targeting CTLA-4 [1]. | |||
T76952 | Zalifrelimab | ||
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody that targets CTLA-4 (CTLA-4), functioning by antagonizing the CTLA-4-signaling-regulated inhibitory checkpoints of immune cell activation. | |||
T77103 | Nurulimab | ||
Nurulimab (BCD-145) is a humanized monoclonal antibody targeting cytotoxic T lymphocyte antigen-4 (anti-CTLA-4). It has potential applications in melanoma research [1]. | |||
T82268 | Gotistobart | BNT 316,ONC-392 | |
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that enhances immunotherapy by selectively depleting regulatory T cells (Treg) within the tumor microenvironment [1]. | |||
T81124 | Sovipostobart | ||
Sovipostobart, an immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 in Homo sapiens, features a cleavable prodomain. This compound serves as both an immunostimulant and antineoplastic [1]. | |||
T76728 | Vudalimab | ||
Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors. | |||
T77072 | Lorigerlimab | ||
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that blocks both PD-1 and CTLA-4, enhancing T-cell responses. It is under investigation for the treatment of metastatic castration-res... | |||
T80598 | Davoceticept | CD80 vIgD-Fc,ALPN-202 | |
Davoceticept (ALPN-202; CD80 vIgD-Fc), a monoclonal antibody that targets CTLA-4, is comprised of the (1-107) fragment of CD80 fused to the IGHG1 Fc domain through a peptidyl linker. It is commonly produced in CHO (Chine... | |||
T76859 | Bavunalimab | ||
Bavunalimab (Anti-Human CTLA4xLAG3), a bispecific human monoclonal antibody targeting CTLA-4 and LAG-3, activates T cells in NSG mice and is utilized in cancer research [1]. | |||
T76933 | Botensilimab | ||
Botensilimab (AGEN 1181), a humanized monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), functions as an activator of both innate and adaptive immunity. It is currently being researched for its pote... | |||
T76968 | Tuvonralimab | ||
Tuvonralimab (PSB-205; QL1706), comprising a combination of Iparomlimab and Tuvonralimab [1], functions as a dual immune checkpoint inhibitor through its formulation of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies. |